Status:
RECRUITING
Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)
Lead Sponsor:
Eye & ENT Hospital of Fudan University
Collaborating Sponsors:
Changhai Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions:
Glottic Carcinoma
Supraglottic Carcinoma
Eligibility:
All Genders
18-90 years
Brief Summary
For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery, open partial laryngectomy, radiotherapy, and transoral robotic surgery were performed accord...
Detailed Description
For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery (CO2 laser resection), open partial laryngectomy (vertical partial laryngectomy, cricohyoidoe...
Eligibility Criteria
Inclusion
- Laryngeal cancer: glottic type, supraglottic type, and subglottic type; hypopharyngeal cancer: pyriform sinus type, postcri-coid type, and posterior pharyngeal wall type.
- T1, T2, T3, and T4 stage.
- Age 18 - 90.
- Male or female.
- Good compliance.
- No other severe related diseases that may impact the treatment (such as other tumors, severe heart, lung and central nervous system diseases, etc.).
- Negative pregnancy test (for female patients with fertility).
- Male patients with fertility and female patients with fertility and pregnancy risk must agree to use contraceptive methods throughout the study period, and continued until at least 6 months after the last dose of cisplatin. Female patients do not have fertility. Female patients with postmenopausal status.
Exclusion
- Patients who have previously been diagnosed with immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related diseases.
- Patients with a known history of active tuberculosis (TB).
- Pregnant women or lactating women.
- The doctors believes that it is inappropriate for patients to participate in the trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including recent time \[within the past year\] or active suicidal ideation or behavior).
Key Trial Info
Start Date :
December 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04908696
Start Date
December 1 2025
End Date
December 1 2027
Last Update
December 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Tao
Shanghai, Shanghai Municipality, China, 200031